Integrated Traditional Chinese and Clinical Medicine for Chronic Hepatitis B and Its Complication
NCT ID: NCT05128305
Last Updated: 2021-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
276 participants
INTERVENTIONAL
2021-12-01
2022-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Moreover, studies have found that the liver and the intestine originate from the same germ layer and are closely related to each other in anatomy and function. There are a large number of microorganisms living in the intestinal tract. Normally, the intestinal tract, as the first defense of the human body, can effectively prevent bacteria and their products from entering the bloodstream. In cirrhosis and portal hypertension, blood return disorder causes intestinal damage. A series of microbes and product endotoxins such as gram-negative bacteria will enter the blood through the injury, and the toxins in the peripheral blood will enter the brain and cause hepatic encephalopathy happened.
The research team's early treatment plan with integrated traditional Chinese and Western medicine proved that it greatly reduced the incidence of hepatic encephalopathy after TIPS. And improve the clinical symptoms and signs of patients with liver cirrhosis, and improve the quality of life and survival of patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1
traditional chinese medicine 1 and traditional chinese medicine 2 simulant
traditional Chinese medicine1 and traditional Chinese medicine 2
We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
group 2
traditional chinese medicine 1 simulant and traditional chinese medicine 2
traditional Chinese medicine1 and traditional Chinese medicine 2
We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
group 3
traditional chinese medicine 1 and traditional chinese medicine 2
traditional Chinese medicine1 and traditional Chinese medicine 2
We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
group 4
traditional chinese medicine 1 simulant and traditional chinese medicine 2 simulant
traditional Chinese medicine1 and traditional Chinese medicine 2
We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
traditional Chinese medicine1 and traditional Chinese medicine 2
We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with liver cirrhosis, portal hypertension, bleeding from esophagus and gastric varices; refractory pleural and ascites due to liver cirrhosis; incomplete portal vein/localized thrombosis in liver cirrhosis or primary and secondary prevention of cirrhosis, portal hypertension, esophagus and gastric varices bleeding.
Exclusion Criteria
* Child-pugh classification of liver function C;
* Those with respiratory and circulatory dysfunction;
* Those whose systemic or focal infections have not been effectively controlled;
* Patients with moderate to severe malnutrition;
* Extensive primary or metastatic liver malignant tumors;
* Those who are highly allergic to the products and drugs used in the treatment process.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qianfoshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lili Cao
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
he First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
fengyan Wang, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CT-2020-1230
Identifier Type: -
Identifier Source: org_study_id